

FINANCIAL DISCLOSURE REPORT FOR CALENDAR YEAR 2016

Report Required by the Ethics
in Government Act of 1978
(5 U.S.C. app. §§ 101-111)

1. Person Reporting (last name, first, middle initial) Ray, J. Thomas	2. Court or Organization U. S. District Court - ED AR	3. Date of Report 07/20/2017
4. Title (Article III judges indicate active or senior status; magistrate judges indicate full- or part-time) U. S. Magis. Judge - Full Time	5a. Report Type (check appropriate type) ☐ Nomination ☐ Date ☐ Initial ☒ Annual ☐ Final 5b. ☒ Amended Report	6. Reporting Period 1/1/2016 to 12/31/2016
7. Chambers or Office Address Richard Sheppard Arnold United States Courthouse 500 West Capitol, Room D 144 Little Rock, AR 72201		
IMPORTANT NOTES: The instructions accompanying this form must be followed. Complete all parts, checking the NONE box for each part where you have no reportable information.		

I. POSITIONS. (Reporting individual only; see pp. 9-13 of filing instructions.)

☐ NONE (No reportable positions.)

	<u>POSITION</u>	<u>NAME OF ORGANIZATION/ENTITY</u>
1.	Trustee	Rollover IRA
2.	Trustee	IRA #1
3.	Trustee	IRA #2
4.	Trustee	Trust #1
5.	Trustee	Trust #2
6.	Trustee	Trust #3

II. AGREEMENTS. (Reporting individual only; see pp. 14-16 of filing instructions.)

☒ NONE (No reportable agreements.)

	<u>DATE</u>	<u>PARTIES AND TERMS</u>
1.		
2.		
3.		

FINANCIAL DISCLOSURE REPORT

Page 2 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

III. NON-INVESTMENT INCOME. *(Reporting individual and spouse; see pp. 17-24 of filing instructions.)***A. Filer's Non-Investment Income**NONE *(No reportable non-investment income.)*DATESOURCE AND TYPEINCOME
(yours, not spouse's)

1. _____

2. _____

3. _____

4. _____

B. Spouse's Non-Investment Income - *If you were married during any portion of the reporting year, complete this section.**(Dollar amount not required except for honoraria.)*NONE *(No reportable non-investment income.)*DATESOURCE AND TYPE

1. _____

2. _____

3. _____

4. _____

IV. REIMBURSEMENTS *— transportation, lodging, food, entertainment.**(Includes those to spouse and dependent children; see pp. 25-27 of filing instructions.)*NONE *(No reportable reimbursements.)*SOURCEDATESLOCATIONPURPOSEITEMS PAID OR PROVIDED

1. _____

2. _____

3. _____

4. _____

5. _____

FINANCIAL DISCLOSURE REPORT

Page 3 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

V. GIFTS. *(Includes those to spouse and dependent children; see pp. 28-31 of filing instructions.)*NONE *(No reportable gifts.)*SOURCEDESCRIPTIONVALUE

1.

2.

3.

4.

5.

VI. LIABILITIES. *(Includes those of spouse and dependent children; see pp. 32-33 of filing instructions.)*NONE *(No reportable liabilities.)*CREDITORDESCRIPTIONVALUE CODE

1.

2.

3.

4.

5.

FINANCIAL DISCLOSURE REPORT

Page 4 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
1. Abbvie C.S.	A	Dividend	K	T	Buy	01/13/16	K		
2. Acadia C.S.		None	J	T	Buy	10/14/16	J		
3. Agios C.S.		None			Sold	04/11/16	J	B	
4. Alexion C.S.		None			Sold	04/11/16	K	B	
5. Allergan C.S.	C	Dividend	N	T	Buy	05/05/16	N		
6. Amgen	B	Dividend	L	T	Buy	11/01/16	L		
7. Bank of America C.S.	A	Dividend	L	T					
8. Barrick Gold C.S.	A	Dividend			Sold	03/07/16	K		
9. Berkshire Hathaway (B) C.S.		None	M	T					
10. Biogen C.S.		None	L	T					
11. BP PLC ADR	B	Dividend			Sold	12/16/16	K		
12. Bristol Meyers C.S.	A	Dividend	K	T					
13. Celgene C.S.		None	M	T	Buy (add'l)	06/27/16	L		
14. Cenovus Energy Inc. C.S.	B	Dividend			Sold	12/30/16	K		
15. Chevron C.S.	D	Dividend	M	T					
16. Cisco C.S.	A	Dividend			Sold	08/18/16	K	D	
17. Corning C.S.	A	Dividend			Sold	01/05/16	K	C	

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$250,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 5 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

18. Conoco Phillips C.S.	C	Dividend	M	T					
19. Dow Chemical Co. C.S.	A	Dividend			Sold	06/06/16	J	D	
20. Eli Lilly C.S.	D	Dividend	N	T	Sold (part)	05/09/16	L	E	
21. Encana Corp. C.S.	A	Dividend	K	T	Sold (part)	12/19/16	J		
22. Enterprise Products C.S.	B	Dividend	K	T	Buy	02/11/16	K		
23. Exxon Mobil Corp. C.S.	D	Dividend	N	T					
24. Fairfax Financial Hldgs C.S.	B	Dividend			Sold	08/10/16	N	F	
25. Freeport McMoran C.S.		None	J	T					
26. Gilead, C.S.	D	Dividend	M	T	Buy (add'l)	10/07/16	M		
27. HP Inc., C.S.	A	Dividend			Sold	01/05/16	K	D	
28. Hewlett Packard ENTE, C.S.		None			Sold	01/05/16	K	D	
29. Intel C.S.	B	Dividend	L	T					
30. J P Morgan Chase C.S.	B	Dividend	L	T					
31. Johnson & Johnson C.S.	D	Dividend	N	T					
32. Lexmark Intl Inc. C.S.	A	Dividend			Sold	01/05/16	K	D	
33. Medivation Inc., C.S.		None			Sold	04/11/16	K	C	
34. Merck & Co. Inc. C.S.	D	Dividend	N	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 6 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

35. National Oilwell Varco C.S.		None			Sold	05/03/16	K		
36. Newmont Mining C.S.	A	Dividend			Sold	02/08/16	L		
37. Peabody Energy Corp. C.S.		None			Sold	01/05/16	J		
38. Permian Basin Trust C.S.	B	Dividend	J	T					
39. Pfizer Inc. C.S.	C	Dividend	L	T					
40. Phillips 66 C.S.	C	Dividend	M	T					
41. Phillips 66 Partners C.S.	B	Dividend	K	T	Buy	10/31/16	K		
42. Precision Drilling C.S.		None			Sold	10/28/16	J		
43. Rio Tinto ADR	A	Dividend			Sold	04/14/16	J		
44. Roche ADR	A	Dividend	K	T	Buy (add'l)	10/21/16	K		
45. Regeneron Inc.		None	M	T	Buy	11/01/16	M		
46. Sanofi Aventis C.S.	C	Dividend	L	T					
47. Seacor Holdings C.S.		None			Sold	06/15/16	K		
48. Seattle Genetics, Inc. C.S.		None	K	T	Buy	02/05/16	K		
49. Stryker Corp. C.S.	A	Dividend	K	T					
50. Teck Resources C.S.		None			Sold	04/21/16	J		
51. Tejon Ranch Co. C.S.		None			Sold	02/05/16	J		

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 7 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

52. Tsakos C.S.	B	Dividend			Sold	12/07/16	K	A	
53. Vale ADR	A	Dividend			Sold	01/05/16	J		
54. Valero Energy C.S.	D	Dividend	M	T					
55. Wells Fargo C.S.	B	Dividend	L	T					
56. Weyerhaeuser Co C.S.	A	Dividend			Sold	01/05/16	J	B	
57. UCA Rev. Bond	A	Interest			Redeemed	05/01/16	K	A	
58. Charles Schwab Money Market (Cash Equivalents)	A	Interest	L	T					
59.									
60. ORI/Acadia & Ver. Par., LA; McGowan Inc.; Zachry Exploration	F	Royalty	N	W					
61. ORI/Regan County, TX/Pioneer Natural Resources	A	Royalty	L	W					
62. W/I; Acadia & Vermillion Par., LA; McGowan Inc.	E	Royalty	N	W					
63. ORI/Acadia Par., LA; Zachry Eploraton (X)	D	Royalty	N	W					
64. Rental Property (Pulaski County, AR)	C	Rent	N	W					
65.									
66. Rollover IRA (H)									
67. Charles Schwab Money Market (Cash Equivalents)	A	Interest	K	T					
68. - Acadia Pharmaceuticals C.S.		None	K	T	Buy	10/27/16	K		

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 8 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
69. - Agios C.S.		None			Sold	04/11/16	K	B	
70. Allergan C.S.	C	Dividend	N	T	Buy	05/06/16	N		
71. - Amgen C.S.	C	Dividend	M	T					
72. - Bank of America. C.S.	A	Dividend	K	T					
73. - Barrick Gold Corp. C.S.	A	Dividend			Sold	03/07/16	K		
74. - Berkshire Hathaway (B) C.S.		None	M	T					
75. - Biogen C.S.		None	L	T					
76. - BP ADR	B	Dividend			Sold	06/17/16	K		
77. - Celgene C.S.		None	M	T	Sold (part)	04/12/16	L	E	
78. - Chevron C.S.	B	Dividend	L	T	Sold (part)	08/10/16	L	C	
79. - Conoco Phillips C.S.	B	Dividend	L	T					
80. - Encana Corp C.S.	A	Dividend			Sold	09/01/16	K		
81. - Exxon C.S.	C	Dividend	L	T					
82. - Freeport McMoran C.S.		None			Sold	02/23/16	K		
83. - General Electric Co. C.S.	A	Dividend			Sold	03/09/16	K	B	
84. - Gilead Sciences Inc. C.S.	C	Dividend	M	T					
85. - J.P. Morgan C.S.	B	Dividend	K	T	Sold (part)	05/12/16	K	D	

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 9 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)

86. - Johnson & Johnson C.S.	C	Dividend	M	T					
87. - Kinder Morgan Inc. C.S.	A	Dividend	K	T					
88. - Merck & Co. Inc. C.S.	B	Dividend	L	T					
89. - Medivation C.S.		None			Sold	08/22/16	L	E	
90. - Pfizer Inc. C.S.	D	Dividend	M	T					
91. - Phillips 66 C.S.	B	Dividend	K	T					
92. - Phillips 66 Partners L.P.	A	Dividend	K	T	Buy	03/10/16	K		
93. - Regeneron C.S.		None	L	T	Buy	11/01/16	L		
94. - Roche Hldg ADR	B	Dividend	K	T					
95. - Sanofi Aventis C.S.	B	Dividend	K	T					
96. - Schlumberger C.S.	A	Dividend			Sold	04/19/16	L	C	
97. - Stemline Therapeutics C.S.		None	K	T					
98. - Transocean Inc. C.S.		None			Sold	06/16/16	J		
99. - Wells Fargo & Co. C.S.	A	Dividend			Sold	10/14/16	K	E	
100. - Whiting Petroleum C.S.		None	J	T	Buy	02/23/16	J		
101.									
102. IRA #1 (H)									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 10 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
103. - Abbvie C.S.	A	Dividend	J	T	Buy	01/13/16	J		
104. - Agios C.S.					Sold	04/11/16	J	A	
105. - Acadia Pharm. C.S.		None	J	T	Buy	10/14/16	J		
106. - Allergan C.S.	A	Dividend	K	T	Buy	05/04/16	K		
107. - Amgen Inc. C.S.	A	Dividend	K	T					
108. - Bank of America C.S.	A	Dividend			Sold	01/06/16	J	A	
109. - Barrick Gold Corp. C.S.	A	Dividend			Sold	01/07/16	J		
110. - Berkshire Hathaway (B) C.S.		None	K	T					
111. - BP PLC C.S.	A	Dividend			Sold	06/17/16	J		
112. - Celgene C.S.		None	K	T					
113. - Conoco C.S.	A	Dividend	J	T					
114. - Dow Chemical Co C.S.	A	Dividend			Sold	06/06/16	J	B	
115. - Exxon Mobil C.S.	A	Dividend	J	T					
116. - Freeport McMoran		None	J	T					
117. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					
118. - Johnson & Johnson C.S.	A	Dividend	K	T					
119. - J.P. Morgan Chase C.S.	A	Dividend	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 11 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS – income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
120. - Merck C.S.	A	Dividend	K	T					
121. - Phillips 66 C.S.	A	Dividend	J	T					
122. - Pfizer C.S.	A	Dividend	K	T					
123. - Stemline Therapeutics C.S.		None	J	T					
124. - Transocean Inc. C.S.		None			Sold	01/07/16	J		
125. - Whiting Petroleum		None			Sold	06/15/16	J	A	
126. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
127.									
128. Inherited IRA (H)									
129. - AbbVie Inc. C.S.	A	Dividend	J	T					
130. - Acadia Pharm. C.S.		None	J	T	Buy	10/14/16	J		
131. - Agios C.S.		None	J	T					
132. - Allergan C.S.		None	K	T					
133. - Alexion C.S.		None			Sold	04/11/16	J	A	
134. - Berkshire Hathaway C.S.		None	K	T					
135. - Biogen Inc. C.S.		None	K	T					
136. - Celgene C.S.		None	J	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 12 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
137. - Chevron C.S.	A	Dividend	J	T					
138. - Coca Cola C.S.	A	Dividend			Sold	01/07/16	J	A	
139. - Conoco Phillips C.S.	A	Dividend	J	T					
140. - Diageo PLC ADR	A	Dividend			Sold	04/11/16	J	A	
141. - Gilead Science Inc. C.S.	A	Dividend	K	T					
142. - Honeywell Inc. C.S.	A	Dividend			Sold	04/11/16	J	A	
143. - Johnson & Johnson C.S.	A	Dividend	J	T					
144. - Medivation Inc. C.S.		None			Sold	08/22/16	J	C	
145. - Merck C.S.	A	Dividend	J	T					
146. - Mondelez C.S.	A	Dividend			Sold	04/11/16	J	A	
147. - Occidental C.S.	A	Dividend			Sold	06/16/16	J	A	
148. - Pfizer C.S.	A	Dividend	J	T					
149. - Proctor & Gamble C.S.	A	Dividend	J	T					
150. - Time Warner Inc. C.S.	A	Dividend			Sold	01/07/16	J	A	
151. - Wells Fargo & Co. C.S.	A	Dividend	J	T					
152. - Whiting Petroleum C.S.		None	J	T					
153. - Dodge & Cox Intl. Stock M.F.	A	Dividend			Sold	04/13/16	J		

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 13 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
154. - Matthews Pacific Tiger M.F.	A	Dividend	J	T					
155. - Pimco Commodities Plus M.F.	A	Dividend			Sold	04/19/16	J		
156. - Preimcap Odyssey Stock M.F.	A	Dividend	J	T					
157. - T. Rowe Price Overseas M.F.	A	Dividend	J	T					
158. - Charles Schwab Money Market (Cash Equivalents) (X)	A	Interest	J	T					
159.									
160.									
161. IRA #2 (H)									
162. - Allergan C.S.		None	J	T	Buy	06/27/16	K		
163. - Amgen Inc. C.S.	A	Dividend	J	T					
164. - Bank of America C.S.	A	Dividend	J	T					
165. - Barrick Gold Corp. C.S.	A	Dividend			Sold	01/07/16	J		
166. - Berkshire Hathaway (B) C.S.		None	K	T					
167. - Celgene C.S.		None	L	T					
168. - Conoco C.S.	A	Dividend	J	T					
169. - Exxon C.S.	A	Dividend	J	T	Sold (part)	06/27/16	J	A	
170. - Gilead Sciences Inc. C.S.	A	Dividend	K	T					

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$50,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 14 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VII. INVESTMENTS and TRUSTS -- income, value, transactions (Includes those of spouse and dependent children; see pp. 34-60 of filing instructions.)

☐ NONE (No reportable income, assets, or transactions.)

A. Description of Assets (including trust assets) Place "(X)" after each asset exempt from prior disclosure	B. Income during reporting period		C. Gross value at end of reporting period		D. Transactions during reporting period				
	(1) Amount Code 1 (A-H)	(2) Type (e.g., div., rent, or int.)	(1) Value Code 2 (J-P)	(2) Value Method Code 3 (Q-W)	(1) Type (e.g., buy, sell, redemption)	(2) Date mm/dd/yy	(3) Value Code 2 (J-P)	(4) Gain Code 1 (A-H)	(5) Identity of buyer/seller (if private transaction)
171. - Johnson & Johnson C.S.	A	Dividend	K	T					
172. - Merck C.S.	A	Dividend	K	T					
173. - Pfizer Inc. C.S.	A	Dividend	K	T					
174. - Charles Schwab Money Market (Cash Equivalents)	A	Interest	J	T					
175.									

1. Income Gain Codes: (See Columns B1 and D4)	A = \$1,000 or less F = \$50,001 - \$100,000	B = \$1,001 - \$2,500 G = \$100,001 - \$1,000,000	C = \$2,501 - \$5,000 H1 = \$1,000,001 - \$5,000,000	D = \$5,001 - \$15,000 H2 = More than \$5,000,000	E = \$15,001 - \$50,000
2. Value Codes (See Columns C1 and D3)	J = \$15,000 or less N = \$250,001 - \$500,000 P3 = \$25,000,001 - \$50,000,000	K = \$15,001 - \$50,000 O = \$500,001 - \$1,000,000	L = \$50,001 - \$100,000 P1 = \$1,000,001 - \$5,000,000 P4 = More than \$5,000,000	M = \$100,001 - \$250,000 P2 = \$5,000,001 - \$25,000,000	
3. Value Method Codes (See Column C2)	Q = Appraisal U = Book Value	R = Cost (Real Estate Only) V = Other	S = Assessment W = Estimated	T = Cash Market	

FINANCIAL DISCLOSURE REPORT

Page 15 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

VIII. ADDITIONAL INFORMATION OR EXPLANATIONS. *(Indicate part of report.)*

Explanation 1: The Note and Mortgage listed in Section VI. of my Financial Disclosure Report, dated August 4, 2016, is no longer being reported because the Note has been paid in full. I now have no liabilities.

Explanation 2: My previous Financial Disclosure Reports have listed assets held in Trust # 1, Trust # 2, and Trust # 3. Beginning in calendar year 2014, filers are only required to report in Part VII assets held in trust if:

- * the filer, the spouse, or dependent child: receives income, or
- * has a beneficial interest in principal or income from the trust or estate.

Pursuant to the above-quoted language from the Filing Instructions for Judicial Officers and Employees, the assets held in Trust # 1, Trust # 2, and Trust # 3 are no longer required to be reported. Accordingly, those assets are not being disclosed in this Financial Disclosure Report, and will not be disclosed in any future Financial Disclosure Reports.

FINANCIAL DISCLOSURE REPORT

Page 16 of 16

Name of Person Reporting

Ray, J. Thomas

Date of Report

07/20/2017

IX. CERTIFICATION.

I certify that all information given above (including information pertaining to my spouse and minor or dependent children, if any) is accurate, true, and complete to the best of my knowledge and belief, and that any information not reported was withheld because it met applicable statutory provisions permitting non-disclosure.

I further certify that earned income from outside employment and honoraria and the acceptance of gifts which have been reported are in compliance with the provisions of 5 U.S.C. app. § 501 et. seq., 5 U.S.C. § 7353, and Judicial Conference regulations.

Signature: **s/ J. Thomas Ray**

NOTE: ANY INDIVIDUAL WHO KNOWINGLY AND WILLFULLY FALSIFIES OR FAILS TO FILE THIS REPORT MAY BE SUBJECT TO CIVIL AND CRIMINAL SANCTIONS (5 U.S.C. app. § 104)

Committee on Financial Disclosure
Administrative Office of the United States Courts
Suite 2-301
One Columbus Circle, N.E.
Washington, D.C. 20544